{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:29:15Z","timestamp":1716078555065},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,9,22]],"date-time":"2013-09-22T00:00:00Z","timestamp":1379808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00280-013-2301-z","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T12:44:43Z","timestamp":1379767483000},"page":"1103-1110","source":"Crossref","is-referenced-by-count":7,"title":["A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)"],"prefix":"10.1007","volume":"72","author":[{"given":"Luis E.","family":"Raez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Timothy","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger A.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Karr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andra","family":"Kennah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrett H.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,22]]},"reference":[{"key":"2301_CR1","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","volume":"21","author":"F Fossella","year":"2003","unstructured":"Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016\u20133024","journal-title":"J Clin Oncol"},{"key":"2301_CR2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2004.11.004","volume":"22","author":"V Georgoulias","year":"2004","unstructured":"Georgoulias V, Ardavanis A, Agelidou A et al (2004) Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22:2602\u20132609","journal-title":"J Clin Oncol"},{"key":"2301_CR3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095\u20132103","journal-title":"J Clin Oncol"},{"key":"2301_CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lungcan.2003.09.001","volume":"43","author":"J Dancey","year":"2004","unstructured":"Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43:183\u2013194","journal-title":"Lung Cancer"},{"key":"2301_CR5","first-page":"785","volume":"23","author":"C Kouroussis","year":"2003","unstructured":"Kouroussis C, Agelaki S, Mavroudis D et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785\u2013791","journal-title":"Anticancer Res"},{"key":"2301_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lungcan.2006.05.023","volume":"53","author":"LE Raez","year":"2006","unstructured":"Raez LE, Santos ES, Lopes G et al (2006) Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 53:347\u2013353","journal-title":"Lung Cancer"},{"key":"2301_CR7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"issue":"(18 suppl)","key":"2301_CR8","doi-asserted-by":"crossref","first-page":"LBA7514","DOI":"10.1200\/jco.2007.25.18_suppl.lba7514","volume":"25","author":"C Manegold","year":"2007","unstructured":"Manegold C, von Pawel J, Zatloukal P (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-na\u00efve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25((18 suppl)):LBA7514","journal-title":"J Clin Oncol"},{"key":"2301_CR9","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","volume":"27","author":"JD Patel","year":"2009","unstructured":"Patel JD, Hensing TA, Rademaker A et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284\u20133289","journal-title":"J Clin Oncol"},{"key":"2301_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2301_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398","journal-title":"N Engl J Med"},{"key":"2301_CR12","volume-title":"Sample size calculations in clinical research","year":"2003","unstructured":"Chow SC, Shao J, Wang H (eds) (2003) Sample size calculations in clinical research. CRC Press, New York, NY"},{"key":"2301_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"2301_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29\u201341","journal-title":"Biometrics"},{"key":"2301_CR15","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn. John Wiley & Sons, Inc., New York, NY","edition":"2"},{"key":"2301_CR16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/cncr.24996","volume":"116","author":"WN William Jr","year":"2010","unstructured":"William WN Jr, Kies MS, Fossella FV et al (2010) Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116:2401\u20132408","journal-title":"Cancer"},{"key":"2301_CR17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","volume":"21","author":"M Reck","year":"2010","unstructured":"Reck M, von Pawel J, Zatloukal P et al (2010) for the BO17704 Study Group. Overall survival with cisplatin\u2013gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol 21:1804\u20131809","journal-title":"Ann Oncol"},{"key":"2301_CR18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(08)70261-4","volume":"9","author":"K Kubota","year":"2008","unstructured":"Kubota K, Kawahara M, Ogawara M et al (2008) for the Japan Multi-National Trial Organisation. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 9:1135\u20131142","journal-title":"Lancet Oncol"},{"key":"2301_CR19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12094-006-0121-x","volume":"8","author":"MC Dols","year":"2006","unstructured":"Dols MC, Chamorro EV, D\u00edaz IA (2006) Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clin Transl Oncol 8:742\u2013749","journal-title":"Clin Transl Oncol"},{"key":"2301_CR20","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2004.10.576","volume":"22","author":"E Laack","year":"2004","unstructured":"Laack E, Dickgreber N, M\u00fcller T et al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348\u20132356","journal-title":"J Clin Oncol"},{"key":"2301_CR21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","volume":"52","author":"O Rixe","year":"1996","unstructured":"Rixe O, Ortuzar W, Alvarez A et al (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute\u2019s Anticancer Drug Screen panel. Biochem Pharmacol 52:1855\u20131865","journal-title":"Biochem Pharmacol"},{"key":"2301_CR22","first-page":"799","volume":"53","author":"W Schmidt","year":"1993","unstructured":"Schmidt W, Chaney SG (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799\u2013805","journal-title":"Cancer Res"},{"key":"2301_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01212608","volume":"123","author":"RC Rietbroek","year":"1997","unstructured":"Rietbroek RC, van de Vaart PJM, Haveman J et al (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123:6\u201312","journal-title":"J Cancer Res Clin Oncol"},{"key":"2301_CR24","first-page":"3500","volume":"54","author":"EL Mamenta","year":"1994","unstructured":"Mamenta EL, Poma EE, Kaufmann WK et al (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500\u20133505","journal-title":"Cancer Res"},{"key":"2301_CR25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00280-009-0943-7","volume":"64","author":"MH Chang","year":"2009","unstructured":"Chang MH, Kim KH, Jun HJ et al (2009) Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 64:917\u2013924","journal-title":"Cancer Chemother Pharmacol"},{"key":"2301_CR26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1179\/joc.2009.21.4.439","volume":"21","author":"A Radhakrishnann","year":"2009","unstructured":"Radhakrishnann A, Bitran JD, Milton DT et al (2009) Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial. J Chemother 21:439\u2013444","journal-title":"J Chemother"},{"key":"2301_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2008.05.028","volume":"63","author":"J Tr\u00e9daniel","year":"2009","unstructured":"Tr\u00e9daniel J, Becht C, Bekradda M et al (2009) An open phase II trial of gemcitabine, oxaliplatin, and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer 63:259\u2013263","journal-title":"Lung Cancer"},{"key":"2301_CR28","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/JTO.0b013e318187273f","volume":"3","author":"RS Heist","year":"2008","unstructured":"Heist RS, Fidias P, Huberman M et al (2008) A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 3:1153\u20131158","journal-title":"J Thorac Oncol"},{"key":"2301_CR29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JTO.0b013e31816de28f","volume":"3","author":"R Lilenbaum","year":"2008","unstructured":"Lilenbaum R, Raez L, Tseng J et al (2008) Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 3:511\u2013515","journal-title":"J Thorac Oncol"},{"key":"2301_CR30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lungcan.2006.09.001","volume":"54","author":"S Kakolyris","year":"2006","unstructured":"Kakolyris S, Ziras N, Vamvakas L et al (2006) Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 54:347\u2013352","journal-title":"Lung Cancer"},{"key":"2301_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6602667","volume":"93","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F, Novello S, De Marinis F et al (2005) Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93:29\u201334","journal-title":"Br J Cancer"},{"key":"2301_CR32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/annonc\/mdh215","volume":"15","author":"JD Winegarden","year":"2004","unstructured":"Winegarden JD, Mauer AM, Otterson GA et al (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15:915\u2013920","journal-title":"Ann Oncol"},{"key":"2301_CR33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdf006","volume":"13","author":"I Monnet","year":"2002","unstructured":"Monnet I, de Cremoux H, Souli\u00e9 P et al (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13:103\u2013107","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2301-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2301-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2301-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:22:59Z","timestamp":1715995379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2301-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2301-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,22]]}}}